[PRTK] Paratek Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 14.2 Change: 0.9 (6.77%)
Ext. hours: Change: 0 (0%)

chart PRTK

Refresh chart

Strongest Trends Summary For PRTK

PRTK is in the medium-term up 22% in 2 months and down -32% below S&P in 1 year. In the long-term down -65% below S&P in 2 years and down -95% below S&P in 13 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines to save lives and alleviate suffering. Its lead product candidate, omadacycline, is a tetracycline-derived, broad-spectrum antibiotic being developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with The Food and Drug Administration (FDA) for the Phase III trials planned in ABSSSI and CABP. Its other product candidate, WC 3035 (sarecycline), is a new tetracycline-derived compound, with dual narrow-spectrum antibacterial and potent anti-inflammatory activity for the treatment of acne and rosacea in the community setting. The company has licensed rights of WC 3035 to Actavis, which has completed Phase II clinical tr

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-27.34% ROE-32.12% ROI
Current Ratio12.91 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities20 K Cash From Investing Activities-140 K Cash From Operating Activities-3.23 M Gross Profit
Net Profit-10.63 M Operating Profit-10.63 M Total Assets99.7 M Total Current Assets94.04 M
Total Current Liabilities7.28 M Total Debt1.42 M Total Liabilities14.85 M Total Revenue
Technical Data
High 52 week15.3 Low 52 week4.8 Last close7.23 Last change0.98%
RSI58.66 Average true range0.28 Beta0.65 Volume179.86 K
Simple moving average 20 days4.47% Simple moving average 50 days14.23% Simple moving average 200 days-17.72%
Performance Data
Performance Week0% Performance Month8.72% Performance Quart-0.55% Performance Half-29.12%
Performance Year-45.23% Performance Year-to-date40.94% Volatility daily2.69% Volatility weekly6.01%
Volatility monthly12.32% Volatility yearly42.66% Relative Volume260.49% Average Volume353.6 K
New High New Low

News

2019-03-20 13:35:44 | Seth Klarman's Small Caps: Worth a Look?

2019-03-18 08:00:00 | Paratek Pharmaceuticals Announces Management Change

2019-03-07 12:47:33 | What Should Investors Know About Paratek Pharmaceuticals, Inc.’s NASDAQ:PRTK Future?

2019-03-01 16:30:00 | Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635c4

2019-03-01 08:00:00 | Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference

2019-02-28 02:19:29 | Edited Transcript of PRTK earnings conference call or presentation 27-Feb-19 9:30pm GMT

2019-02-27 21:08:07 | Paratek Pharmaceuticals Inc PRTK Q4 2018 Earnings Conference Call Transcript

2019-02-27 16:01:00 | Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-20 10:31:03 | Will Paratek Pharmaceuticals PRTK Report Negative Earnings Next Week? What You Should Know

2019-02-14 16:05:00 | Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference

2019-02-13 16:05:00 | Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019

2019-02-06 17:05:00 | New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ Omadacycline For Pneumonia and Skin Infections

2019-02-06 08:23:47 | The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

2019-02-05 16:05:00 | Paratek Pharmaceuticals Launches NUZYRA™ Omadacycline in the United States

2019-02-01 16:01:00 | Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635c4

2019-01-18 11:09:32 | What You Must Know About Paratek Pharmaceuticals, Inc.’s NASDAQ:PRTK Beta Value

2019-01-17 10:00:00 | Antimicrobials Working Group Announces Updates to Leadership Team

2019-01-02 16:01:00 | Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635c4

2018-12-16 02:47:12 | Arbiter Partners Capital Management’s Returns, AUM and Holdings

2018-12-06 23:50:24 | Hedge Funds Are Selling Paratek Pharmaceuticals Inc PRTK

2018-12-06 07:30:00 | Analysis: Positioning to Benefit within Paratek Pharmaceuticals, Chesapeake Utilities, Eros International, Sunoco LP, Delek Logistics Partners, and Johnson Controls International plc — Research Highlights Growth, Revenue, and Consolidated Results

2018-12-03 16:01:00 | Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030

2018-11-27 08:00:00 | Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections

2018-11-15 12:28:01 | Do Institutions Own Paratek Pharmaceuticals Inc NASDAQ:PRTK Shares?

2018-11-07 07:16:01 | Edited Transcript of PRTK earnings conference call or presentation 6-Nov-18 9:30pm GMT

2018-11-06 17:50:10 | Paratek Pharmaceuticals PRTK Reports Q3 Loss, Misses Revenue Estimates

2018-11-06 16:48:32 | Paratek: 3Q Earnings Snapshot

2018-11-06 16:02:00 | Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results

2018-11-01 16:05:00 | Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635c4

2018-10-26 16:05:00 | Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018

2018-10-26 08:45:00 | Investor Expectations to Drive Momentum within Paratek Pharmaceuticals, Dell Technologies, Dover, Black Hills, Kinder Morgan, and Novo Nordisk A/S — Discovering Underlying Factors of Influence

2018-10-25 13:12:43 | War against the superbugs: Mass. biotechs step up to fight antibiotic resistance

2018-10-22 13:56:07 | 5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout

2018-10-05 10:55:00 | Major Action in Biotech and This is The Next Winner

2018-10-04 16:30:00 | Why Barnes & Noble, Paratek Pharmaceuticals, and Hortonworks Jumped Today

2018-10-04 16:01:00 | Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline

2018-10-04 08:40:12 | Paratek Pharmaceuticals PRTK in Focus: Stock Moves 8.7% Higher

2018-10-03 16:05:00 | Paratek Pharmaceuticals, Inc. to Host Investor Day on October 23, 2018

2018-10-03 12:45:31 | FDA Approves Paratek's Bacterial Pneumonia, Skin Infection Treatment

2018-10-03 12:43:59 | Paratek gets second FDA approval in past 24 hours

2018-10-03 10:37:02 | Paratek PRTK Gets FDA Approval for Nuzyra and Seysara

2018-10-03 08:53:12 | Implied Volatility Surging for Paratek Pharmaceuticals PRTK Stock Options

2018-10-03 08:00:00 | Today's Research Reports on Trending Tickers: Paratek Pharmaceuticals and Trevena

2018-10-02 19:18:21 | US regulators OK updated version of decades-old antibiotic

2018-10-02 08:45:00 | FDA Approves SEYSARA™ Sarecycline for the Treatment of Moderate to Severe Acne

2018-10-01 16:01:00 | Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635c4

2018-09-26 07:40:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Sina, Paratek Pharmaceuticals, Honda Motor Co., Prospect Capital, G1 THERAPEUTICS, and Gaming and Leisure Properties — New Research Emphasizes Economic Growth

2018-09-25 08:00:00 | Paratek Pharmaceuticals Presenting New Omadacycline Data at IDWeek 2018

2018-09-04 16:30:00 | Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635c4

2018-08-30 06:21:37 | Mass. antibiotics developers say the field is getting slowly better